L-371,257
Prijeđi na navigaciju
Prijeđi na pretragu
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| 1-[4-[(1-Acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]-4-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl)piperidine | |||
| Klinički podaci | |||
| Identifikatori | |||
| CAS broj | 162042-44-6 | ||
| ATC kod | ? | ||
| PubChem[1][2] | 6918320 | ||
| Hemijski podaci | |||
| Formula | C28H33N3O6 | ||
| Mol. masa | 507.577 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
L-371,257 je lek koji se koristi u naučnim istraživanjima. On deluje kao selektivni antagonist oksitocinskog receptora sa preko 800x većom selektivnišću u odnosu na vazopresinske receptore.[3] On je bio jedan od prvih nepeptidnih oksitocinskih antagonista.[4][5][6][7] Ovaj materijal ima dobru oralnu bioraspoloživost i lošu penetraciju kroz krvno-moždanu barijeru što mu daje dobru perifernu selektivnost sa malim brojem centralnih nuspojava.[8] Ovo jedinjenje potencialno može da nađe primenu u sprečavanju preranog porđaja.[9]
Literatura[uredi | uredi kod]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Williams PD, Clineschmidt BV, Erb JM, Freidinger RM, Guidotti MT, Lis EV, Pawluczyk JM, Pettibone DJ i dr.. (1995). „1-(1-4-(N-acetyl-4-piperidinyl)oxy-2-methoxybenzoylpiperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist”. Journal of medicinal chemistry 38 (23): 4634–6. DOI:10.1021/jm00023a002. PMID 7473590.
- ↑ Bell IM, Erb JM, Freidinger RM, Gallicchio SN, Guare JP, Guidotti MT, Halpin RA, Hobbs DW i dr.. (1998). „Development of orally active oxytocin antagonists: studies on 1-(1-4-1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy-2- methoxybenzoylpiperidin-4-yl)-1,4-dihydrobenzd1,3oxazin-2-one (L-372,662) and related pyridines”. Journal of medicinal chemistry 41 (12): 2146–63. DOI:10.1021/jm9800797. PMID 9622556.
- ↑ Kuo MS, Bock MG, Freidinger RM, Guidotti MT, Lis EV, Pawluczyk JM, Perlow DS, Pettibone DJ i dr.. (1998). „Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus”. Bioorganic & medicinal chemistry letters 8 (21): 3081–6. DOI:10.1016/S0960-894X(98)00568-X. PMID 9873680.
- ↑ Williams PD, Bock MG, Evans BE, Freidinger RM, Gallicchio SN, Guidotti MT, Jacobson MA, Kuo MS i dr.. (1999). „Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency”. Bioorganic & medicinal chemistry letters 9 (9): 1311–6. PMID 10340620.
- ↑ Wyatt PG, Allen MJ, Chilcott J, Foster A, Livermore DG, Mordaunt JE, Scicinski J, Woollard PM (2002). „Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives”. Bioorganic & medicinal chemistry letters 12 (10): 1399–404. DOI:10.1016/S0960-894X(02)00159-2. PMID 11992786.
- ↑ Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B, Schechter LE, Rizzo S i dr.. (2006). „Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications”. Psychopharmacology 185 (2): 218–25. DOI:10.1007/s00213-005-0293-z. PMID 16418825.
- ↑ Hawtin SR, Ha SN, Pettibone DJ, Wheatley M (2005). „A Gly/Ala switch contributes to high affinity binding of benzoxazinone-based non-peptide oxytocin receptor antagonists”. FEBS letters 579 (2): 349–56. DOI:10.1016/j.febslet.2004.10.108. PMID 15642343.
